The 300mg/150mg tablets are licensed in combination with other antiretrovirals for the treatment of HIV-1 infected patients without known mutations associated with atazanavir resistance.
Click to search or browse MIMS
The most up-to-date drug information at your fingertips.
- Get the prescribing support you need.
- Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Access the full drug database and quick-reference tables on the go